; or (ii) increases the average manufacturer price for the applicable drug above the fair price (increased by the consumer price index for all urban consumers (as published by the Bureau of Labor Statistics) for that year), the Office shall revoke the purchaser’s approved application and resume production of the applicable drug. The Office may waive the application of this subparagraph in the case of a National Emergency or in any other case determined appropriate by the Office. (d) Ensuring patient access (1) In general The Office shall carry out appropriate activities to ensure the distribution and coverage of all applicable drugs that the Office is manufacturing or has entered into a contract to manufacture under this section. (2) Advisory council The Office shall establish an advisory council to inform the Office on the identification of applicable drugs, market landscape, and supply chain considerations to ensure delivery of applicable drugs to consumers. The advisory committee shall include representatives from community and retail pharmacies, pharmacy benefit managers, drug wholesalers, hospitals, health plans, independent patient groups, clinicians, and consumer advocacy organizations. (e) Insulin Not later than 1 year after the date of enactment of this section, the Office shall begin the public manufacturing of at least 1 insulin product of each dosage form (such as vial, pump, or pen dosage forms) and of each different type of insulin (such as rapid-acting, short-acting, intermediate-acting, long-acting, ultra-long acting, and premixed), meeting the definition of applicable drug and in accordance with this section. (f) Asthma and COPD inhalers Not later than 1 year after the date of enactment of this section, the Office shall begin the public manufacturing of at least 1 inhaler, meeting the definition of applicable drug and in accordance with this section. (g) Epinephrine auto-Injector Not later than 1 year after the date of enactment of this section, the Office shall begin the public manufacturing of